Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q3 FY25 results · Oct–Dec 2024
Alkem Laboratories reported revenue from operations of ₹3,374.28 crore (up 1.5% from Q3 FY24) and net profit of ₹640.79 crore (up 6.0% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,374.28 | 3,323.87 | +1.5% | 3,414.67 | −1.2% |
| Other income | 92.99 | 93.64 | −0.7% | 134.48 | −30.9% |
| Total income | 3,467.27 | 3,417.51 | +1.5% | 3,549.15 | −2.3% |
| Profit before tax | 731.07 | 654.90 | +11.6% | 780.26 | −6.3% |
| Net profit for the period | 640.79 | 604.28 | +6.0% | 701.96 | −8.7% |
| Attributable to shareholders of the company | 625.82 | 594.96 | +5.2% | 688.64 | −9.1% |
| EPS, basic (₹) | 52.34 | 49.76 | +5.2% | 57.60 | −9.1% |
| Net margin (%) | 19.0 | 18.2 | 20.6 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,286.83 | 2,494.59 | −8.3% | 2,871.97 | −20.4% |
| Other income | 169.18 | 95.66 | +76.9% | 120.19 | +40.8% |
| Total income | 2,456.01 | 2,590.25 | −5.2% | 2,992.16 | −17.9% |
| Profit before tax | 738.40 | 534.38 | +38.2% | 767.67 | −3.8% |
| Net profit for the period | 723.12 | 504.23 | +43.4% | 697.58 | +3.7% |
| EPS, basic (₹) | 60.48 | 42.17 | +43.4% | 58.34 | +3.7% |
| Net margin (%) | 31.6 | 20.2 | 24.3 |
Consolidated
- Filed with BSE
- 07 Feb 2025, 18:07 IST
- Board meeting
- 07 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2025, 18:07 IST
- Board meeting
- 07 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE